T-CiRA is a 10-year-long joint research program between Takeda and Kyoto University's Center for iPS Cell Research and Application (CiRA) led by Prof. Shinya Yamanaka, a Nobel Prize-winning researcher. T-CiRA is engaged in cutting-edge research into the clinical applications of iPS (induced pluripotent stem) cell technology. The team is working on the development of regenerative medicine and drug discovery, determined to provide patients with innovative treatment methods.
Clinical Operations teams play a critical role in the development of new treatments. Responsible for operational management of clinical trials, they are at the center of the lengthy process of taking a drug candidate through all phases to become an approved treatment available to patients.
Immunotherapy is gaining more attention in oncology as the latest therapy after surgery, radiotherapy, and chemotherapy, At Takeda’s research center in Boston, many researchers including him are working hard to develop new medicines of this cutting-edge modality.
She works in clinical development, a role in which she focuses on a particular medicine and investigates how to move it forward for the beneﬁt of patients. That might mean designing trials to receive approval by one of the regulatory agencies or, if it’s already been approved, looking at how it can be developed further to make it even more valuable for patients.
As one of Takeda’s internal auditor, he assesses, reports and provides recommendations for improvements on the Takeda Group governance, risk management and internal control processes of all the company’s domestic and international entities. This is a crucial part of improving business operations and keeping the organization healthy.
The role of investor relations (IR) is to keep shareholders and investors informed so that they can make investment decisions with conﬁdence. Through this, the value of the company can then be evaluated appropriately. The importance of the role becomes very apparent when challenging situations in the company arise.
She engages as a Medical Science Liaison (MSL), the role of having scientific conversation with doctors who see patients on a daily basis and working with them to pave the way to better treatments for symptoms that are not addressed by current medicines.
Takeda Announces Introduction of New, Highly Flexible Work Styles
Takeda Japan has introduced a highly flexible work system in order to further promote the reform of working practices and respond to employees' life-work needs. Find out more about the positive changes to work styles here.
An introduction to the LIFE CAFÉ, a place to recharge the body and mind. Located at the 20th floor at Takeda Global Headquarters in Tokyo, the café serves a selection of delicious, nutritional food throughout the day in a stylish space with panoramic views of Tokyo.
Takeda Global Headquarters Grand Opening
Takeda’s Global Headquarters in Nihonbashi, Tokyo, Japan was opened in July 2018. The building serves as a base and a symbol of our values, and will support our transformation into a global biopharmaceutical leader that brings better health and a brighter future to people worldwide. Find out more about the opening and Creative Director Kashiwa Sato's design concept here.
His job at Takeda involves working with international organizations to develop policies that improve access to medicines for people worldwide. Find out more about why he joined the company, and what aspects of the corporate philosophy he relates to the most.
"As part of a team of researchers, our work begins with the need to solve a problem, then quickly becomes a mission: to develop medicines that can help patients.”
Find out more about her team’s approaches to R&D and passing on the “baton of hope.”
Takeda completes the construction of the Takeda Global Headquarters in Tokyo, designed to provide an environment that supports the diverse work styles and the connectivity of colleagues from around the world. Find out more about the exterior, location and functions of the new building.
He is a drug discovery chemist who leads a team that designs and synthesizes drug candidates. His goal is to become the best team of our kind in the world. Find out more about this challenge of developing new drugs.
T-CiRA is a joint research program conducted with the Kyoto University Center for iPS Cell Research and Application (CiRA). T-CiRA researchers share what drives them in their work on cutting-edge projects.
“I am in charge of our drug substance manufacturing processes.” He explains each stage of API production and the stringent quality checks that have to take place.
“I am in charge of the marketing for an anticancer drug for multiple myeloma.” Hear more about her work on the oncology marketing team and the importance of her award-winning packaging design.
Our new office building located in Nihonbashi, Tokyo, is due for completion on March 16, 2018, with the grand opening event scheduled for July 2018. Designed to accelerate innovation, the interior creative direction is helmed by Kashiwa Sato of SAMURAI INC. Find out more here.